New insights into prostate cancer biology.
Prostate cancer is common, biologically heterogeneous, and protean in its clinical manifestations. Through the use and analysis of isogenic cell lines, xeno-grafts, transgenic mice, and human tumors, one begins to deconvolute the precise biologic mechanisms that combine to create the native complexity and heterogeneity of this disease. In this article, the authors have underscored compelling recent discoveries in prostate cancer so as to provide the reader with molecular paradigms with which to interpret future insights into its biology. Although it was inevitably necessary to omit a significant amount of important research in prostate cancer, the work discussed here is exemplary of current prostate cancer research. Looking forward, it is hoped that the collective work of mapping genetic and biologic interactions among key regulators of prostate epithelial cells, epithelial-stromal interactions, host immune system, and host genetics will eventually result in a comprehensive understanding of prostate cancer. Although it is likely that the molecular characteristics of an individual's prostate cancer will be analyzed using limited molecular tools in the near future, eventual application of genomic technologies and nanotechnology offers the promise of robust future characterization. Such a characterization is likely to be required to maximize our ability to optimize and individualize preventive and treatment strategies.
Balakumaran
Bala S
BS
Duke Institute for Genome Sciences and Policy, Duke University, Durham, NC 27708, USA.
Febbo
Phillip G
PG
D023281:Genomics; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D015513:Oncogene Proteins / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000209:etiology*; D011944:Receptors, Androgen / Q000378:metabolism; D015398:Signal Transduction; D025521:Tumor Suppressor Proteins / Q000378:metabolism
D015513:Oncogene Proteins; D011944:Receptors, Androgen; D025521:Tumor Suppressor Proteins